| Website | antigenics.com |
| Category | BioTech |
| Phone | 212-994-8200 |
| Employees | |
| Founded | 2000 |
| Description | biotechnology company |
| TOTAL | $9.35M |
| VENTURE FUNDING TOTAL | $9.35M |
| Venture Round, 8/09 Iroquois Capital Downsview Capital Hudson Capital Management | $9.35M |
Antigenics, Inc., a biotechnology company, develops treatments for cancers and infectious diseases. It offers Oncophage, a personalized therapeutic cancer vaccine candidate, which is in Phase III clinical trials for the treatment of renal cell carcinoma and for metastatic melanoma. The company’s products also include Aroplatin, a liposomal chemotherapeutic, which is in Phase I clinical trial for the treatment of solid tumors and non-Hodgkin’s lymphoma; AG-707, a therapeutic vaccine program that is in Phase I clinical trial for the treatment of genital herpes; and QS-21, an adjuvant used in various vaccines, including hepatitis, lyme diseases, human immunodeficiency virus, influenza, cancer, Alzheimer’s disease, and malaria. The company was founded as Antigenics L.L.C. in 1994 and changed its name to Antigenics, Inc. in 2000. Antigenics is headquartered in New York, New York.
